Genmab — September 2020

E_L

Blood Advances: Teclistamab is an active T cell–redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma https://ashpublications.org/bloodadvances/article/4/18/4538/463776/Teclistamab-is-an-active-T-cell-redirecting

E_L

it seems I was correct that a decision on Camidanlumab had to be taken this summer:

E_L

ADCT looking to raise money again: ADC Therapeutics Announces Proposed Public Offering https://www.nasdaq.com/press-release/adc-therapeutics-announces-proposed-public-offering-2020-09-21

E_L

which means we get a SEC report : https://sec.report/Document/0001140361-20-020981/#nt10014672x2_f1.htm

E_L

where on p6 it reads "Our collaboration and license agreement with Genmab may require a divestment of Cami, in which Genmab has a 25% interest. On June 24, 2020, we and Genmab agreed to enter into a period of good faith negotiations regarding the key financial terms of our license agreement. " etc etc

E_L

this may be a good Cami summary: "we are evaluating Cami in a 100-patient pivotal Phase 2 clinical trial for the treatment of relapsed or refractory HL and have enrolled 47 patients as of June 30, 2020.

E_L

We have completed enrollment of a 133-patient Phase 1 clinical trial of Cami for the treatment of relapsed or refractory HL and NHL that has shown an 86.5% ORR and a 48.6% CRR in patients with HL at the initial dose for our pivotal Phase 2 clinical trial and a 44.0% ORR and an 8.0% CRR in a subset of patients with T-cell lymphoma as of April 2019.

E_L

We anticipate reporting top-line response rate data from our pivotal Phase 2 clinical trial of Cami for the treatment of HL in the first half of 2021, and we believe that this clinical trial, if successful, will support a BLA submission.

E_L

We are also evaluating Cami in a Phase 1b clinical trial as a novel immuno-oncology approach for the treatment of various advanced solid tumors.

E_L

More on the Collaboration and License Agreement is on p167 if interested

AaBforever

GENMAB/SHB: KURSMÅL HÆVES TIL 2400 KR. FRA 1920 KR./ritzau/FINANS

Darvin

Det "lovede" de jo sådan set også den anden dag

Darvin

Men - de er slet ikke færdige

Sukkeralf

Good work again E L

E_L

and finally in exhibit 10.6 it reeds "The Parties agree to negotiate for a period ending on 31 August 2020 with the intent to agree in good faith on a non-binding term sheet that includes all key financial terms for a license agreement between the Parties whereby ADCT acquires Genmab’s share of the ADC"

E_L

so looks as if Genmab is trying to divest it

E_L

ADCT better raise a lot of money then so they can afford the payoff

lahn1

Nogen der ved hvilket samarbejde Genmab har med U-Protein Express i Utrecht ?

kkjoel

So, must we assume that they have closed the agreement (31 Aug 2020) and/or will GEN be obliged to publish the main terms upon signing it?

kkjoel

Btw, great find, EL